The study examined the relationship between systemic inflammation and prognosis in 60 patients with neuroendocrine neoplasia treated between 2016–2023. The researchers analyzed three biomarkers derived from routine blood counts: the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and the systemic immune inflammation index (SII). 38.3% of patients died during follow-up. Multivariate analysis revealed that advanced age, poorly differentiated histology (neuroendocrine carcinoma) and increased SII were significantly associated with increased mortality. In conclusion, the study identifies SII, NLR and PLR as available, reliable and cost-effective biomarkers with prognostic value. Integration of these indices with established clinicopathological features may improve risk stratification and personalized patient management. However, the authors emphasize the need to validate these findings in larger and prospective cohorts.